EGFR and non-small cell lung carcinoma: As the presence of concomitant mutations were shown to affect the activity of first-line EGFR TKIs in a subgroup of EGFR mutant NSCLC tumors [18], the same could occur in patients harboring the KRAS concomitant mutations found in the present study.